USPH VS NVO Stock Comparison

Performance

USPH
100/100

USPH returned 2.89% in the last 12 months. Based on SPY's performance of -13.44%, its performance is above average giving it a score of 100 of 100.

NVO
100/100

NVO returned 70.22% in the last 12 months. Based on SPY's performance of -13.73%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

USPH
61/100

7 analysts offer 12-month price targets for USPH. Together, they have an average target of 0, the most optimistic target put USPH at 0 within 12-months and the most pessimistic has USPH at 0.

NVO
50/100

1 analysts offer 12-month price targets for NVO. Together, they have an average target of 0, the most optimistic target put NVO at 0 within 12-months and the most pessimistic has NVO at 0.

Sentiment

USPH
67/100

USPH had a bullish sentiment score of 66.64% across Twitter and StockTwits over the last 12 months. It had an average of 2.88 posts, 0.12 comments, and 0.00 likes per day.

NVO

"Sentiment" not found for NVO

Technicals

USPH
50/100

USPH receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

NVO
50/100

NVO receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

USPH
69/100

USPH has missed earnings 2 times in the last 20 quarters.

NVO
46/100

NVO has missed earnings 3 times in the last 20 quarters.

Profit

USPH
61/100

Out of the last 20 quarters, USPH has had 20 profitable quarters and has increased their profits year over year on 5 of them.

NVO
90/100

Out of the last 20 quarters, NVO has had 20 profitable quarters and has increased their profits year over year on 15 of them.

Volatility

USPH
55/100

USPH has had a higher than average amount of volatility over the last 12 months giving it a score of 54 of 100.

NVO
53/100

NVO has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Dividend

USPH
19/100

USPH's most recent dividend was $0.82 per share, based on a share price of $87.22. It was a payout ratio of 95.21% compared to their total earnings.

NVO

"Dividend" not found for NVO

All score calculations are broken down here to help you make more informed investing decisions

US Physical Therapy Inc Summary

New York Stock Exchange / USPH

Healthcare

Medical - Care Facilities

U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. The company offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. As of December 31, 2021, it operated 591 clinics in 39 states; and managed 35 physical therapy practice facilities. The company was founded in 1990 and is based in Houston, Texas.

Novo-Nordisk A/S Summary

New York Stock Exchange / NVO

Healthcare

Biotechnology

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Power up your portfolio